UCART123 – Clinical Trial Open to Recruitment

Research FOR Patients
-For an informed and empowered opinion-

All the trials listed in our site have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust - for the continuous work in updating the listing.


  1. SUB-TYPE OF MDS:Patients newly diagnosed with CD123 positive adverse genetic risk acute myeloid leukaemia (AML), including patients with CD123 positive AML secondary to MDS
  3. NAME OF DRUG: UCART targeting CD123 positive leukaemia cells
  4. Aims and benefits: This is a phase 1 first in human study to determine the safety and effectiveness of multiple infusions of UCART123 (specially engineered T-cells that target leukaemia cells that express CD123).

  1. Basic inclusion criteria:
    • Aged 18 - 65 years
    • Weight ≥42 kg
    • Patients must have received 1 of the 2 trial-stipulated induction chemotherapy regimens
    • Availability of a suitable sibling or unrelated HLA matched donor
    • ECOG performance status of 0 or 1
  2. Basic exclusion criteria:
    • Patients with ≥ 20% blasts in bone marrow after 1 or 2 courses of standard intensive induction chemotherapy
    • Patients with AML transformed from previously diagnosed myeloproliferative disorder
    • Patients with APL
    • Evidence of CNS leukaemia on CSF examination
    • AML relapsing after first complete remission
    • Prior allogeneic stem cell transplant
    • Therapy-related AML
    • Favourable or intermediate risk AML
    • Prior gene or experimental cellular therapy
    • HIV/HBV/HCV Infection
  3. Trial sites/locations and name of physician in charge of trial (none are currently recruiting):
    • Kings College Hospital

Please read information and always discuss trial information with your own physician.

Free donations by shopping